SCHEMBL4370877

SCHEMBL4370877

C#Cc1ccc(-c2cccc(CN[C@@H](CCC(N)=O)C(=O)OC(=O)c3ccc(-c4ccccc4)cc3)c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEP1B Q16820 2/20 0.37
MMP2 P08253 2/20 0.36
MMP9 P14780 2/20 0.36
PADI3 Q9ULW8 2/20 0.36
PADI4 Q9UM07 2/20 0.36
BCL2 P10415 1/20 0.36
HPGDS O60760 1/20 0.36
F10 P00742 1/20 0.35
PRSS1 P07477 1/20 0.35
SLC1A5 Q15758 1/20 0.35
CTSL P07711 1/20 0.35
CTSB P07858 1/20 0.35
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
FFAR1 O14842 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4361261 0.85 MGLL (0.46) KDM4EHPGDSFFAR1
SCHEMBL5655905 0.85 KDM4E (0.42) KDM4EMEP1BMMP2MMP9HPGDS
SCHEMBL4362592 0.83 HPGDS (0.47) KDM4EMMP2MMP9HPGDSFFAR1
SCHEMBL2244761 0.81 F2 (0.38) KDM4EMEP1BBCL2F10PRSS1
SCHEMBL2247351 0.81 CYP4F2 (0.38) AOC3KDM4EMEP1BBCL2F10
SCHEMBL2247552 0.80 FFAR1 (0.44) MEP1BMMP2MMP9FFAR1
SCHEMBL4369490 0.79 KDM4E (0.44) KDM4EMMP2MMP9SLC1A5
SCHEMBL4365892 0.79 KDM4E (0.42) KDM4EMMP2MMP9F10PRSS1
SCHEMBL5653527 0.79 SMN1; SMN2 (0.47) KDM4EMMP2MMP9SLC1A5FFAR1
SCHEMBL2247824 0.79 POLB (0.37) KDM4EMEP1BF10PRSS1FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US disclosed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043066-A1 Glutamate aggrecanase inhibitors ADAMTS5, ADAMTS1, ADAMTS7 AOC3 1803/4885KDM4E 1232/4885MEP1B 2803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.